Emerging data suggest this peptide, a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , may offer a significant step forward for obesity treatment. Preliminary clinical tests have indicated considerable losses in abdominal mass , potentially outperforming existing weight-loss medications . Despite this, more as